Top-News
Biotechnologie Israel

Chemomab Therapeutics Ltd ADR/20 Aktie

Aktie
WKN:  A3CMJ9 ISIN:  US16385C1045 US-Symbol:  CMMB
1,42 $
+0,06 $
+4,41%
1,2558 € 20:14:37 Uhr
Depot/Watchlist
Aktienanzahl *
10,37 Mio.
Marktkapitalisierung *
12,08 Mio. €
Streubesitz
58,04%
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 24.09.2024

Chemomab Therapeutics Ltd ADR/20 News

12.09.24 - wallstreetONLINE Redaktion
Vom Start-up zum Megacap: Peter Thiel: Mit Palantir zu 9,5 Mrd. USD! Dies sind seine weiteren Aktien
Der Investor Peter Thiel konnte zuletzt mit Palantir Technologies wieder einen großen Erfolg feiern. Diese Aktien hält er derzeit außerdem. Peter Thiel prägt die Technologie- und ...
07.03.24 - PR Newswire
Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update
Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update PR Newswire
05.03.24 - PR Newswire
Chemomab Therapeutics to Participate in Leerink Global BioPharma Conference
Chemomab Therapeutics to Participate in Leerink Global BioPharma Conference PR Newswire
20.02.24 - PR Newswire
Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases
Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-​Inflammatory Diseases PR Newswire
14.02.24 - PR Newswire
Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update
Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update PR Newswire
05.02.24 - PR Newswire
Chemomab Therapeutics to Participate in Upcoming Investor Conferences
Chemomab Therapeutics to Participate in Upcoming Investor Conferences PR Newswire
30.01.24 - PR Newswire
Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis
Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis PR Newswire
03.01.24 - PR Newswire
Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024
Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024 PR ...
16.11.23 - PR Newswire
Chemomab Presentation at ACR Convergence 2023 Provides Further Support for Key Role of Its CCL24 Target in the Pathogenesis of Systemic Sclerosis
Chemomab Presentation at ACR Convergence 2023 Provides Further Support for Key Role of Its CCL24 Target in the Pathogenesis of Systemic Sclerosis PR Newswire
15.11.23 - PR Newswire
Chemomab Therapeutics Receives FDA Fast Track Designation for CM-101 for the Treatment of Primary Sclerosing Cholangitis
Chemomab Therapeutics Receives FDA Fast Track Designation for CM-101 for the Treatment of Primary Sclerosing Cholangitis PR Newswire
13.11.23 - PR Newswire
Chemomab Presents New Clinical Data Supporting CM-101's Anti-Fibrotic/Anti-Inflammatory Activity in Patients with Liver Fibrosis and New Data Highlighting Unique Association of Its CCL24 Target with Key PSC Pathways at AASLD's The Liver Meeting® 2023
Chemomab Presents New Clinical Data Supporting CM-101's Anti-​Fibrotic/Anti-​Inflammatory Activity in Patients with Liver Fibrosis and New Data Highlighting Unique Association of ...
09.11.23 - PR Newswire
Chemomab Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
Chemomab Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update PR Newswire
06.11.23 - PR Newswire
Chemomab Therapeutics Discloses Receipt of Nasdaq Notice Regarding Minimum Bid Price Requirement
Chemomab Therapeutics Discloses Receipt of Nasdaq Notice Regarding Minimum Bid Price Requirement PR Newswire
30.10.23 - PR Newswire
Chemomab Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update
Chemomab Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update PR Newswire
26.10.23 - PR Newswire
Chemomab Therapeutics to Present at Upcoming Scientific Conferences
Chemomab Therapeutics to Present at Upcoming Scientific Conferences PR Newswire
28.09.23 - PR Newswire
Chemomab Therapeutics to Present Its CM-101 Clinical Program in Primary Sclerosing Cholangitis at 2023 Roth MKM Healthcare Opportunities Conference
Chemomab Therapeutics to Present Its CM-101 Clinical Program in Primary Sclerosing Cholangitis at 2023 Roth MKM Healthcare Opportunities Conference PR Newswire
29.08.23 - PR Newswire
Chemomab Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Chemomab Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference PR Newswire
14.08.23 - PR Newswire
Chemomab Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Corporate Update
Chemomab Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Corporate Update PR Newswire
28.06.23 - PR Newswire
Chemomab Therapeutics Announces Publication in JCI Insight Demonstrating Key Role of CCL24 in Primary Sclerosing Cholangitis
Chemomab Therapeutics Announces Publication in JCI Insight Demonstrating Key Role of CCL24 in Primary Sclerosing Cholangitis PR Newswire
26.06.23 - PR Newswire
Chemomab Therapeutics Presents Data Reinforcing the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2023
Chemomab Therapeutics Presents Data Reinforcing the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2023 PR Newswire

Newssuche

Videos

newspaper
30.04.25 +22,47%
Technical Trading: Cotton Long Chance
Cotton Long Typ: Turbo Open End WKN: VP6N8D Hebel: 3,80 Laufzeit: OpenEnd Einstieg: Market ... Mehr »